Solera Health will integrate the BlueStar® Digital Therapeutic, a diabetes management solution, into its national network of Diabetes Prevention Program providers
Phoenix, AZ, and Columbia, MD, January 17, 2018 – Solera Health, an integrated benefit network, and WellDoc®, a leading digital therapeutic company, announced today that WellDoc’s BlueStar® digital therapeutic will join the Solera network as a diabetes management solution of choice. The partnership aligns both companies’ goals to improve the lives of those living with chronic diseases while enhancing clinical results and decreasing overall healthcare costs. Solera Health connects patients, payers and physicians with community organizations and digital therapeutics providers delivering evidence-based prevention, coping and support services. The company’s national and scalable model of integrating highly fragmented non-medical programs and services into an integrated network helps individuals identify the “best fit” program provider based on their unique needs and preferences. Solera’s model is driving industry-leading sustained engagement and outcomes and lessening the administrative burden for payers to access a broad network of high-performing solutions providers.
“The addition of BlueStar to our network of evidence-based solution providers enables Solera to offer a broader, more comprehensive approach to diabetes prevention and management that drives sustained consumer engagement and clinical outcomes,” said Brenda Schmidt, CEO of Solera Health. “WellDoc is an ideal partner to help fill this need as BlueStar delivers impressively on both — individual commitment and clinically-validated results — as evidenced by the data we’ve seen to date.”
WellDoc’s FDA-cleared, proven digital therapeutic, BlueStar, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personalized for each individual. WellDoc is the first digital health company to conduct randomized clinical trials that demonstrate significant clinical outcomes1, as published in more than 30 peer-reviewed journals and posters presented at leading industry conferences. Truven
Health Analytics®, part of the IBM Watson Health™ business, recently conducted an analysis for WellDoc using the MarketScan® Research Databases. By WellDoc applying these new Truven Health findings to previous research it conducted about BlueStar’s ability to lower and control A1C, the data show that BlueStar can save on average a range of $254 to $271 per user per month.
“We’re honored to join Solera Health’s network of preferred digital therapeutic solution providers for diabetes management,” said WellDoc President and CEO Kevin McRaith. “Partnering with Solera Health is a natural next step as we continue to expand access to BlueStar via health plans, health systems and employers.”
Solera Health is an integrated health network that connects patients, payers, and physicians with community organizations and digital therapeutics providers, simply and securely. Solera helps consolidate highly fragmented programs and services into one integrated network, allowing health plans and medical providers to increase consumer participation while lowering associated costs. Solera proactively identifies the “best fit” program provider based on each individual’s unique needs and preferences, which has proven to have a significant impact on improved patient outcomes at a fraction of the cost of traditional medical care. For more information, visit Solera Health at www.soleranetwork.com, call 800-858-1714 or follow us on Twitter @SoleraHealth or LinkedIn.
WellDoc® is a leading digital health company revolutionizing chronic disease management to help transform lives. Our groundbreaking technology is guiding individuals through the complicated journey of living with chronic diseases, with a goal of improving their health and helping them to be more balanced. We are the first digital health company based on a life science business model with a foundation that is built on randomized clinical trials that demonstrate significant clinical outcomes. We have mastered diabetes management by taking an aggressive and innovative approach that utilizes sophisticated logic and precise algorithms, and integrates the most advanced mobile technology, behavioral insight, and diabetes education for those living with type 2 diabetes.
Our FDA-cleared, proven digital therapeutic, BlueStar®, provides real-time and timely individualized coaching and support, as well as diabetes educational tools that are actionable and personal. Our clinical evidence shows a 1.7 to 2.0-point mean A1C reduction for adults living with type 2 diabetes who used BlueStar®. In November 2017, the IQVIA Institute for Human Data Science (formerly Quintiles/IMS) named BlueStar the “top app” in clinical diabetes
treatment. For more information, visit www.welldoc.com.
Jessy Green & Kay Kelly
SVM Public Relations for Solera
1 Quinn CC, et al. Diabetes TechnolTher.2008 ;10(3) :160-168. Quinn CC, et al. Diabetes Care. 2011: 34:
Richard Katz, MD; George Washington University Medical Center; Journal of Health Communication,
Quinn, CC, et al. Glycemic Control: Impact on Physician Prescribing Behavior, Presentation ADA
72ndScientific Sessions, 2012.
Tang PY, et al. eHealth-Assisted Lay Health Coaching for Diabetes Self-Management Support American
Diabetes Association 76th Scientific Sessions Poster Presentation 2016 Presented at AADE San Diego 2016.